The phase III SANDPIPER trial demonstrated a modest, but statistically significant, enhancement in PFS with the taselisib and fulvestrant combination, as opposed to fulvestrant monotherapy, in ER+ advanced breast cancer patients who had encountered progression during or subsequent to aromatase inhibitor (AI) therapy (41). Here, CYP19A1 is linked to breast cancer.